Opendata, web and dolomites

BREAK SIGNED

Blue light remote analgesia with K+ channels

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BREAK project word cloud

Explore the words cloud of the BREAK project. It provides you a very rough idea of what is the project "BREAK" about.

initiated    nonspecific    neuropathic    minutes    originally    np    kept    optogenetic    difficult    skin    thirds    abnormal    network    antidepressants    treatment    rats    plan    invasive    distance    hours    implant    blue    disorder    drugs    20    addiction    nausea    version    pain    partial    medical    actually    trauma    gt    blink2    worse    peripheral    vivo    constitute    invasiveness    stakeholder    adoption    restraining    despite    causing    experiments    cp    origin    pharma    entities    lower    class    patients    centers    adults    characterised    reporting    optical    brain    situation    fruitful    population    weeks    area    cells    explore    commercial    12    light    virus    normally    central    extremely    painful    stimuli    genes    prolonged    exact    spectrum    mostly    solution    neuron    first    hospitals    global    drug    leveraging    companies    silencing    treatments    relief    tool    diagnose    hard    protein    chronic    engineered    investor    progress    lamp    opioids    academic    proteins    demonstrated    device    damage    treat    interpret    injected    nervous    synergy    leads    designed    inhibitory    break    illness    genetically    cm      

Project "BREAK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 150˙000.00

Map

 Project objective

Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains extremely hard to treat, with only one-third to two-thirds of patients reporting adequate some pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population and whose origin mostly depend on peripheral or central nervous damage or disorder, which leads the brain to interpret as pain normally non painful stimuli. NP is difficult to treat due to the large number of entities involved (cells, genes and proteins working in synergy), which makes it hard to rapidly diagnose the exact cause of pain. Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction, and nausea, thus restraining their adoption for prolonged treatments. BREAK is the first non-invasive inhibitory optogenetic tool specifically designed for NP treatment, with potential application to the whole spectrum of CP. BREAK is composed of a drug and an optical device. The protein BLINK2 is injected in the painful area using a genetically engineered virus, and respond to a specific blue light by silencing the addressed neuron. The lamp can be kept at some distance (cm) from the skin and no implant is required. Just some minutes of treatment results in hours of pain relief, making the invasiveness of BREAK far lower than actually existing solution. A first version of BREAK has already demonstrated in in-vivo experiments on rats. During this project we plan to further develop the treatment and explore its commercial potential. In particular, leveraging from the experience of different partners, we will constitute a fruitful stakeholder network, including Academic centers, hospitals, pharma companies and investor

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREAK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREAK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

NanoMechShape (2019)

Molecular control of actin network architecture and mechanics during cell shape changes

Read More  

RTMFRM (2019)

Room Temperature Magnetic Resonance Force Microscopy

Read More  
lastchecktime (2022-09-28 19:51:41) correctly updated